NasdaqGM - Delayed Quote USD

MediciNova, Inc. (MNOV)

Compare
1.8500 +0.0400 (+2.21%)
At close: October 16 at 4:00 PM EDT
Loading Chart for MNOV
DELL
  • Previous Close 1.8100
  • Open 1.7800
  • Bid 1.3200 x 200
  • Ask 2.3200 x 200
  • Day's Range 1.7800 - 1.8700
  • 52 Week Range 1.1200 - 2.1600
  • Volume 28,060
  • Avg. Volume 38,465
  • Market Cap (intraday) 90.735M
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1600
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

www.medicinova.com

13

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MNOV

View More

MNOV: Phase 3 ALS Readout in 2025…

MNOV: Multiple Abstracts Presented at 92nd EAS Congress…

Performance Overview: MNOV

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MNOV
23.33%
S&P 500
22.49%

1-Year Return

MNOV
7.50%
S&P 500
35.00%

3-Year Return

MNOV
51.57%
S&P 500
30.66%

5-Year Return

MNOV
74.20%
S&P 500
95.03%

Compare To: MNOV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MNOV

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    88.77M

  • Enterprise Value

    44.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    88.77

  • Price/Book (mrq)

    1.55

  • Enterprise Value/Revenue

    44.63

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -9.51%

  • Return on Equity (ttm)

    -13.32%

  • Revenue (ttm)

    1M

  • Net Income Avi to Common (ttm)

    -8.16M

  • Diluted EPS (ttm)

    -0.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.34M

  • Total Debt/Equity (mrq)

    0.86%

  • Levered Free Cash Flow (ttm)

    -6.55M

Research Analysis: MNOV

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 1M
Earnings -723.11k
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

6.00
8.00 Average
1.8500 Current
10.00 High
 

Company Insights: MNOV

People Also Watch